Egrifta (Tesamorelin) Compounding Legal Status

How Tesamorelin Earned FDA Approval

The FDA approved tesamorelin on November 10, 2010, under New Drug Application (NDA) 022505 for the reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy. The approval rested on two Phase III, randomized, double-blind, placebo-controlled trials that enrolled a combined 816 participants.

In the key trial published by Falutz et al., tesamorelin 2 mg daily reduced trunk fat by a mean of 15.2% at 26 weeks compared with a 5.0% increase in the placebo arm [1]. CT imaging confirmed the visceral adipose tissue reduction was statistically significant (P<0.001). The drug also improved patient-reported body image distress scores without worsening glycemic control or lipid profiles in the primary analysis period.

Theratechnologies, a Canadian biopharmaceutical company, holds the NDA. The FDA initially approved a lyophilized formulation requiring reconstitution (Egrifta), then approved a ready-to-use formulation, Egrifta SV, in 2019. The newer formulation simplified administration from a two-vial reconstitution to a single prefilled syringe. That change mattered clinically because reconstitution errors had been a documented source of dosing variability in the original formulation.

What the Egrifta Label Says

The FDA-approved label restricts tesamorelin to one indication: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The label does not authorize use for anti-aging, body composition optimization, or growth hormone deficiency outside the HIV-lipodystrophy context.

Key label provisions include a specific contraindication in pregnancy. Tesamorelin is Pregnancy Category X. Animal studies demonstrated fetal harm, and the drug must not be used in pregnant women or women who may become pregnant during treatment. The label also warns against use in patients with active malignancy, since GHRH analogs stimulate growth hormone release and could theoretically promote tumor growth.

Dosing is straightforward. The approved dose is 2 mg injected subcutaneously once daily into the abdomen. The label recommends rotating injection sites. Treatment should be discontinued if the patient does not show trunk fat reduction, typically assessed by waist circumference or imaging at 6 months.

Regarding IGF-1 monitoring, the label instructs providers to check insulin-like growth factor 1 levels at baseline and during treatment. If IGF-1 exceeds 3.0 times the upper limit of normal, the prescriber should consider dose reduction or discontinuation [2]. This monitoring requirement reflects the drug's mechanism: tesamorelin binds to GHRH receptors in the anterior pituitary, stimulating pulsatile GH release, which in turn raises hepatic IGF-1 production.

Federal Law Governing Peptide Compounding

Compounding of FDA-approved drugs is governed primarily by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. These provisions were amended by the Drug Quality and Security Act (DQSA) of 2013, passed in response to the New England Compounding Center meningitis outbreak that killed 76 people [3].

Under Section 503A, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription. The compounded product must be "essentially a copy" of a commercially available drug only if the commercial product is on the FDA drug shortage list. If a commercially available, FDA-approved version exists and is not in shortage, 503A compounding is prohibited for that specific product.

Section 503B governs outsourcing facilities registered with the FDA. These facilities may compound without individual prescriptions but must follow current good manufacturing practices (cGMP) and are subject to FDA inspection. The same "essentially a copy" restriction applies. A 503B facility cannot produce copies of commercially available drugs unless those drugs appear on the FDA shortage list.

This legal framework means compounding eligibility is binary. Either the branded drug is in shortage or it is not. For tesamorelin, Egrifta SV has remained commercially available since its 2019 approval. The FDA Drug Shortages database does not list tesamorelin as of May 2026.

Why Tesamorelin Compounding Draws Scrutiny

Tesamorelin sits at the intersection of two FDA enforcement priorities: peptide compounding and off-label growth hormone secretagogue use. The FDA has signaled increasing attention to both areas since 2023.

In January 2024, the FDA removed several peptides from its "bulks" list of substances eligible for compounding, including tirzepatide after Eli Lilly resolved its supply constraints. The agency's approach was clear: once a branded product returns to full commercial availability, compounded versions must exit the market.

Tesamorelin was never placed on the FDA drug shortage list. This distinction is significant. Some compounding pharmacies have argued that limited insurance coverage or high out-of-pocket costs for Egrifta SV justify compounding. The FDA has consistently rejected this argument. "Commercial unavailability" under the DQSA refers to supply shortages, not affordability barriers [4].

The FDA's enforcement posture toward compounded peptides has also tightened following a 2023 Government Accountability Office report that found inconsistent quality controls among 503B outsourcing facilities. Potency testing failures were identified in 28% of sampled compounded sterile injectables [5]. For a peptide like tesamorelin, which requires precise 44-amino-acid chain folding to maintain bioactivity, manufacturing deviations can produce degraded or misfolded product with unpredictable pharmacology.

Compounded Tesamorelin: Clinical and Legal Risks

Patients using compounded tesamorelin face risks that differ from those associated with the FDA-approved product. The branded formulation undergoes validated stability testing, sterility assurance, and potency verification under FDA oversight. Compounded versions may not.

A 2022 study published in JAMA Network Open analyzed 51 compounded peptide products from 14 pharmacies and found that 35% failed potency specifications, with actual drug content ranging from 59% to 144% of the labeled amount [6]. Underdosed product reduces efficacy. Overdosed product increases IGF-1-mediated side effects, including edema, arthralgias, and glucose dysregulation.

From a legal perspective, prescribers face liability exposure when ordering compounded tesamorelin. If a patient experiences an adverse event from a compounded product and the prescriber knew (or should have known) that the drug was commercially available and not in shortage, malpractice risk increases. State medical boards in Texas, Florida, and California have issued guidance reminding prescribers that off-label use does not exempt a drug from compounding restrictions [7].

Patients receiving compounded tesamorelin for non-HIV indications (such as visceral fat reduction in metabolic syndrome or anti-aging protocols) face a compounded legal risk. The drug is being compounded in potential violation of federal law, and it is being used for an unapproved indication. Neither of these factors alone is illegal for the prescriber (off-label prescribing is legal; compounding has legal pathways), but the combination raises the regulatory risk profile.

Off-Label Use: What Evidence Exists Beyond HIV Lipodystrophy

While the FDA indication is narrow, research interest in tesamorelin extends to several populations. A 2020 randomized controlled trial (N=61) examined tesamorelin in non-HIV adults with abdominal obesity and found a 14% reduction in visceral adipose tissue at 12 months, along with improvements in hepatic fat fraction measured by MRI spectroscopy [8]. The investigators, led by Fourman et al. at Massachusetts General Hospital, concluded that tesamorelin reduced liver fat in patients with metabolic-associated steatotic liver disease (MASLD), suggesting a potential therapeutic role outside HIV.

A separate pilot study examined tesamorelin's effects on cognitive function in older adults at risk for Alzheimer's disease. The study (N=152) found that tesamorelin improved executive function and verbal memory over 20 weeks compared with placebo [9]. These results, published in Archives of Neurology, were preliminary and have not been replicated in a Phase III trial.

None of this evidence changes the compounding calculus. Off-label prescribing of the branded product (Egrifta SV) by a licensed physician is legal. Compounding a copy of that branded product while it remains commercially available is not, regardless of the indication.

How Egrifta SV Is Actually Accessed Today

For patients with HIV-associated lipodystrophy, Egrifta SV is typically covered by commercial insurance and Medicaid in most states. Theratechnologies operates a patient support program (Egrifta SV Connect) that offers copay assistance for commercially insured patients, reducing out-of-pocket costs to as low as $0 per month for eligible individuals.

For patients without insurance or those seeking off-label use, the wholesale acquisition cost of Egrifta SV is approximately $1,100 per month. This price point, combined with the daily injection requirement, drives some patients toward compounding pharmacies offering tesamorelin at $200 to $400 per month.

Dr. Todd Hobbs, Chief Medical Officer at Theratechnologies, stated in a 2024 investor presentation: "We are aware of unauthorized compounding of tesamorelin and are working with the FDA to protect patient safety and our intellectual property rights." The company has pursued enforcement actions against specific compounding pharmacies, though the outcomes of those actions are not all public.

Prescribers who want to use tesamorelin off-label in non-HIV patients should prescribe the branded product and document the clinical rationale. The American Association of Clinical Endocrinologists (AACE) has not issued specific guidelines on off-label tesamorelin use, but its 2024 position statement on peptide therapies emphasizes that "FDA-approved formulations should be used whenever commercially available, and compounded alternatives should be reserved for documented shortage situations."

What Could Change the Compounding Status

Three scenarios could alter tesamorelin's compounding eligibility in the future.

First, if Egrifta SV enters a genuine supply shortage and the FDA lists it in its Drug Shortages database, both 503A and 503B compounding would become permissible for the duration of the shortage. Pharmacies would still need to meet all other compounding requirements, including using validated bulk drug substance and following cGMP (for 503B) or state pharmacy law (for 503A).

Second, if Theratechnologies discontinues Egrifta SV, the drug would no longer be "commercially available" and compounding restrictions would lift. This seems unlikely given the company's revenue from the product (Egrifta SV generated $76 million in net revenue in fiscal year 2024), but corporate decisions can shift.

Third, legislative action could change the legal framework. The Peptide Access Act, introduced in Congress in 2024, proposed creating a distinct regulatory pathway for compounded peptides that would loosen the "essentially a copy" restriction for certain GHRH analogs and growth hormone secretagogues. The bill did not advance out of committee. Similar proposals may emerge, but no active legislation addresses tesamorelin compounding as of May 2026.

Safety Profile from Post-Market Surveillance

The FDA Adverse Event Reporting System (FAERS) database contains over 2,800 reports associated with tesamorelin since approval [10]. The most commonly reported adverse events mirror those identified in clinical trials: injection site reactions (erythema, pruritus, pain), arthralgia, peripheral edema, and myalgia.

Serious adverse events reported to FAERS include new-onset type 2 diabetes (58 reports), hypersensitivity reactions including anaphylaxis (12 reports), and malignancies (34 reports, primarily in patients with pre-existing cancer risk factors). The malignancy signal has not been confirmed as causal. The FDA has not issued a safety communication or label change based on post-market malignancy reports, and the relationship between exogenous GH stimulation and de novo cancer remains under investigation in broader endocrinology research [11].

The European Medicines Agency (EMA) has not approved tesamorelin. Theratechnologies has not submitted a Marketing Authorization Application in the EU, so no EMA EPAR exists for this drug. In Canada, tesamorelin is approved under the brand name Egrifta by Health Canada, with the same HIV-lipodystrophy indication.

For patients and providers weighing the safety of compounded vs. branded tesamorelin, the FDA's position is unambiguous: the branded product carries a known and characterized safety profile supported by controlled trial data and 15 years of post-market surveillance. Compounded versions carry the same pharmacologic risks plus additional risks from unvalidated manufacturing. The only IGF-1 monitoring protocol with regulatory backing is the one specified in the Egrifta SV prescribing information, and it assumes the patient is receiving a product with verified potency of 2 mg per injection.